Who Exports Ustekinumab from India — 23 Suppliers Behind a $1.3M Market
India's ustekinumab export market is supplied by 23 active exporters who collectively shipped $1.3M across 276 shipments. NIVIRA EXPORTS leads with a 23.6% market share, followed by GNH INDIA PHARMACEUTICALS LIMITED and BIOCON BIOLOGICS INDIA LIMITED. The top 5 suppliers together control 70.8% of total export value, reflecting a concentrated market structure.
Top Ustekinumab Exporters from India — Ranked by Export Value
NIVIRA EXPORTS is the leading ustekinumab exporter from India, holding a 23.6% share of the $1.3M market across 276 shipments from 23 exporters. The top 5 suppliers — NIVIRA EXPORTS, GNH INDIA PHARMACEUTICALS LIMITED, BIOCON BIOLOGICS INDIA LIMITED, VAMA LIFECARE PRIVATE LIMITED, R B INTERNATIONAL — collectively control 70.8% of total export value, indicating a highly concentrated market. Individual shares are: NIVIRA EXPORTS (23.6%), GNH INDIA PHARMACEUTICALS LIMITED (18.9%), BIOCON BIOLOGICS INDIA LIMITED (12.6%), VAMA LIFECARE PRIVATE LIMITED (9.9%), R B INTERNATIONAL (5.9%).
Top Ustekinumab Exporters from India
Ranked by export value · 23 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | NIVIRA EXPORTS INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $299.9K | 1 | 23.6% |
| 2 | GNH INDIA PHARMACEUTICALS LIMITED INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $240.5K | 1 | 18.9% |
| 3 | BIOCON BIOLOGICS INDIA LIMITED BMAB 1200 USTEKINUMABUSTEKINUMAB BMAB 1200 INTERNALUSTEKINUMAB | $160.7K | 2 | 12.6% |
| 4 | VAMA LIFECARE PRIVATE LIMITED INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $126.1K | 1 | 9.9% |
| 5 | R B INTERNATIONAL INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMABSTELARA 90MG/1ML USTEKINUMAB 90MG B NCS4VME M 03/23 E 02/26STELARA 90MG/1ML USTEKINUMAB 90MG B NGS0PMD M 07/23 E 06/26 | $74.6K | 1 | 5.9% |
| 6 | AMERICAN MIDDLE EASTERN MEDICAL SOLUTIONS PRIVATE | $57.9K | 1 | 4.5% |
| 7 | IKRIS PHARMA NETWORK PRIVATE LIMITED INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $50.0K | 1 | 3.9% |
| 8 | SPECIALITY MEDICINES LIMITED INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $46.8K | 1 | 3.7% |
| 9 | MEDICINE HOUSE INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $36.9K | 1 | 2.9% |
| 10 | WELLNESS PHARMA INTERNATIONAL INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $25.5K | 1 | 2.0% |
| 11 | ANR HEALTH CARE PRIVATE LIMITED STELARA 90MG/1ML USTEKINUMAB 90MG B NCS4VME M 03/23 E 02/26STELARA 90MG/1ML USTEKINUMAB 90MG B NGS0PMD M 07/23 E 06/26PHARMACEUTICAL PRODUCTS STELARA 90MG USTEKINUMAB | $17.9K | 1 | 1.4% |
| 12 | TIMES MEDICAMENT PRIVATE LIMITED INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $15.6K | 1 | 1.2% |
| 13 | MATSUN EXPORTS INDIAN HARMLESS PRODUCT STELARA 90MG USTEKINUMAB | $13.5K | 1 | 1.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Ustekinumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| BIOCON BIOLOGICS INDIA LIMITED | Not Listed | Yes, as of June 2023 | Yes | Not verified | WHO-GMP certified in June 2023; EU GMP compliant. |
| SERUM INSTITUTE OF INDIA PRIVATE LIMITED | Not Listed | Yes, as of April 202 | Yes | Not verified | WHO-GMP certified in April 2022; EU GMP compliant. |
| PIRAMAL PHARMA LIMITED | Not Listed | Yes, as of February | Yes | Not verified | WHO-GMP certified in February 2025; EU GMP compliant. |
TransData Nexus reviewed the regulatory standing of 3 leading Ustekinumab exporters from India. 0 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Ustekinumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. Hyderabad's Genome Valley, India's first biotech cluster, provides advanced R&D infrastructure and a skilled talent pool, fostering innovation in biologics and biosimilars.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and is home to major companies like Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. The region's robust infrastructure, including well-connected ports and a supportive regulatory environment, makes it a strategic location for the manufacturing and export of finished pharmaceutical products.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for the pharmaceutical industry. With 929 pharmaceutical units, Maharashtra is a significant contributor to India's pharma sector. The region's proximity to major ports facilitates efficient international distribution, making it a preferred location for companies focusing on export-oriented manufacturing.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 manufacturing units. The region's growth has been propelled by favorable government policies, including tax incentives and a conducive business environment. Baddi's strategic location and infrastructure have attracted numerous pharmaceutical companies, contributing significantly to India's healthcare manufacturing capabilities.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with supplier concentration, consider engaging with multiple suppliers across different clusters.
- Evaluate Supplier Capabilities: Assess the technical expertise and production capacities of potential suppliers, especially for complex biologics like ustekinumab.
- Ensure Regulatory Compliance: Verify that suppliers adhere to international quality standards and possess necessary certifications for export.
- Leverage Cluster Specializations: Align sourcing strategies with the unique strengths of each pharmaceutical cluster to optimize supply chain efficiency.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Ustekinumab exporters from India
Biocon Biologics India Limited — Biocon Biologics acquires Viatris's biosimilars business for $3.34 billion
Biocon Biologics completed the acquisition of Viatris's global biosimilars business, gaining immediate access to commercial infrastructure, regulatory approvals, and a portfolio of over 20 biosimilar assets, including those in oncology, diabetes, and autoimmune therapies. - IMPACT: This acquisition is expected to enhance Biocon Biologics' capabilities in biosimilar production, potentially increasing its Ustekinumab export capacity.
Impact: This acquisition is expected to enhance Biocon Biologics' capabilities in biosimilar production, potentially increasing its Ustekinumab export capacity.
Common Questions — Ustekinumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which ustekinumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, NIVIRA EXPORTS leads with 61 recorded shipments worth $299.9K. GNH INDIA PHARMACEUTICALS LIMITED (33 shipments) and BIOCON BIOLOGICS INDIA LIMITED (5 shipments) are also established high-volume exporters.
Q How many ustekinumab manufacturers are there in India?
India has 23 active ustekinumab exporters with a combined export market of $1.3M across 276 shipments to 10 countries. The top 5 suppliers hold 70.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for ustekinumab from India?
Average FOB unit price: $1300.56 per unit, ranging from $0.05 to $4650.58. Average shipment value: $4.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 23 verified Indian exporters of Ustekinumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 276 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 10 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
276 Verified Shipments
23 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists